PD-1 (programmed cell death-1) inhibitors such as nivolumab and pembrolizumab have been shown to have promising anti-tumor activity in the second-line treatment of HCC and have been approved by the FDA for HCC patients, who were previously treated with sorafenib (9, 10). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.